Recommended Adult Immunization Schedule, by vaccine and age group - KSID, 2012

Age group Vaccine	19~29 years	30~39 years	40~49 years	50~64 years	≥ 65 years			
Tetanus-Pertussis- Diphtheria	then boost with	ap for Td booster; Id every 10 years ngth I)	1-time dose with Tdap; Td at 1 and 6 months; then Td booster every 10 years (strength I) (Tdap only for adults under 65 years old)					
Influenza		1 dose annually (strength III)		1 dose annually (strength I)				
Hepatitis A	2 doses (at 0 and 6 months) (strength II)		oses (at 0 and 6 months) ngth II)	For high-risk groups ^a , check serology; 2 doses for seronegatives (at 0 and 6 months) (strength II)				
Hepatitis B	When 3-doses of immuni	zation uncertain, vaccinate the	For high-risk groups ^{b)} with uncertain immunization history of 3-doses, vaccinate seronegatives (strength III)					
Measles/mumps/ rubella	For high-risk groups ^{c)} , at least 1 dose; check rubella IgG for women planning a pregnancy (strength II)							
Varicella	serone	eck serology; 2 doses for gatives gth II)						
Human Papillomavirus	Female (strength II)							
Meningococcal	For high-risk groups ^e , 1 or 2 doses (strength II)							
Pneumococcal	For high-risk groups ⁰ , 1 dose (strength I)							
Zoster				1 dose (strength U)	1 dose (strength III)			

For all persons in this category who meet the age requirements

Recommended for adults if other risk factor is present

No recommendation

- Tdap = Adult Tetanus-Pertussis-Diphtheria; Td = Adult Tetanus-Diphtheria
- For persons aged ≤15 years, follow the recommendations by the Korean Pediatric Society
- For persons aged 16-18 years, if no other recommendation, follow the recommendation of those aged 19-29 years

Strengths of recommendation

- (I) Very strongly recommended: immunization may reduce mortality and be cost-effective. Most countries recommend the vaccination.
- (II) Strongly recommended: immunization may reduce mortality but cost-effectiveness is unknown in Korea. Most developed countries recommend the vaccination.
- (III) Recommended: immunization may reduce morbidity rather than mortality. Cost-effectiveness is unknown.
- (U) Recommendation reserved: lack of evidence for recommendation.
- a) Hepatitis A (high-risk group): persons with chronic liver disease; persons working at child-care facilities; medical personnel and laboratory workers with potential risk of exposure to the hepatitis A virus; food handlers working at restaurants; persons traveling to or working in countries where hepatitis A is endemic; persons who receive blood products frequently; men who have sex with men; IV drug users; and persons who have had contact with acute hepatitis A patients within 2 weeks.
- b) Hepatitis B (high-risk group): men who have sex with men; sexually active persons with more than one partner; human immunodeficiency virus (HIV) patients; IV drug users; household contacts and sexual partners of persons with hepatitis B virus (HBV) carriers; patients with chronic renal failure; patients with chronic liver disease; workers who are frequently exposed to HBV; and clients and staff members of institutions for persons with developmental disabilities.

 meningococcal conjugate vaccine every 5 years for adults who remain at increased risk for infection.

 f) Pneumococcal (high-risk group): chronic lung disease (including asthma); chronic cardiovascular disease; diabetes; chronic liver disease; chronic renal failure; nephrotic syndrome; functional or anatomical asplenia; immunocompromised patients (congenital
- c) Measles-mumps-rubella (vaccination recommended for high-risk group): Although serological tests (especially for measles) can be done for laboratory evidence of immunity, vaccination without serological tests would be cost saving. High-risk groups: healthcare personnel (serological test required, 2 doses); persons traveling to developing countries; family members who take care of immunocompromised patients; and students who dwell in dormitories.
- d) Varicella: vaccination recommended for high-risk group if serological tests reveal no evidence of immunity. High-risk groups: healthcare workers; family contacts of immunocompromised patients; teachers and child-care employees; students; military personnel; residents of correctional institutions; non-pregnant women expecting pregnancy; adolescents and adults living in households with children; and international trayelers.

- e) Meningococcal (high-risk group): persons with anatomical or functional asplenia; persons with complement component deficiencies; military personnel (especially for recruits); laboratory workers exposed to meningococcus; persons who travel to or live in an endemic area, particularly if their contact with local populations will be prolonged; and college students living in dormitories. The 2-dose series is recommended for adults with anatomical or functional asplenia, complement component deficiency, and HIV infection; 2 doses should be administered at 0 and 2 months. Revaccinate with meningococcal conjugate vaccine every 5 years for adults who remain at increased risk for infection.
- Pneumococcal (high-risk group): chronic lung disease (including asthma); chronic cardiovascular disease; diabetes; chronic liver disease; chronic renal failure; nephrotic syndrome; functional or anatomical asplenia; immunocompromised patients (congenital immunodeficiency, HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, other malignancy, solid organ transplantation), (vaccinate with 3 or 4 doses of protein conjugate vaccine for hematopoietic stem cell transplants); prolonged use of high-dose corticosteroids or immunosuppressive agents; and cochlear implants. One-time revaccination is recommended for persons aged 65 years or older if they were vaccinated 5 or more years previously and they were less than 65 years of age at the time of primary vaccination. One-time revaccination after 5 years is recommended for patients with chronic renal failure, nephrotic syndrome, functional or anatomical asplenia, immunocompromised conditions, and prolonged use of immunosuppressive agents.

Vaccines that might be indicated for adults, based on medical and other indications

vaccinie.	tilat	migi	it be i	Halou	teu ic	n addit	s, busc	u on mic	dicai and	othici	man	atio	13	
	Chronic	Chronic	Chronic	Chronic		Solid organ	0.51	01	Recipients of		HIV infection			0.145
	liver diseases	kidney disease	lung diseases	Cardio- vascular diseases	Diabetes	Cancers receiving chemotherapy	Solid organ transplantation	Stem cell transplantation	immunosuppressants other than transplantation	Asplenia	CD4 <200/µl	CD4 ≥200/µℓ	Pregnancy	Soldier on dut
Influenza														
Pneumococcal														
Td/Tdap							Tdap	DTaP/ Tdap						
Hepatitis A							a)							
Hepatitis B														
Varicella														
MMR														
Meningococcal														
Zoster														
Hib														

	Vaccinations indicated based on medical and other conditions	1
	Vaccinations based on general recommended schedule	
	Contraindicated	
	No recommendation	
,	Hepatitis A vaccination is indicated for adult patients for liver transplantation.	
b)	Vaccinations may be considered 24 months after transplantation provided there is no evidence of graft-versus-host reaction.	

Recommended Immunizations for Healthcare Personnel

Vaccinations regardless of health-care personnel positions (refer to the Recommended Adult Immunization Schedule)						
Adult tetanus-diphtheria (Td)	1 dose every 10 years					
Human papillomavirus	Females in their 10s through 26 years old					
Hepatitis A For persons aged <30 years, vaccinate without serology check; For persons aged ≥ 30 years, vaccinate only seronegatives						
Upon hiring, vaccinate only seronegatives, with uncertain history of immunization						
Hepatitis B	Check serology at the beginning; 3 doses for seronegatives, then check serology after 1-2 months \rightarrow Revaccinate with 3 for seronegatives \rightarrow Check serology after 1-2 months, but no revaccination even if seronegative					
Varicella	For those born in 1970 or later ^{a)} , check serology upon hiring; 2 doses for seronegatives (at 0, 1-2 months)					
Upon hiring, vaccinate without serology check						
Influenza	Annually					
Tetanus-diphtheria-pertussis (Tdap)	1 time dose					
MMR	For those born in 1967 or later ^{b)} , 2 doses prior to starting employment					
Additional vaccination while prevalent in healthcare facilities or for those who work in the laboratory						

a) No study has been done regarding criteria for age in Korea, yet 40 years of age is set as a cutoff.

Meningococcal polysaccharide vaccine (MPSV4)

b) When certain immunization history of 2 doses or diagnosis of measles, mumps, and rubella made by a medical doctor exists, serology check or vaccination is not needed.

Recommended Adult Immunizations for Foreign Travel

Vaccines	Regions recommended Characteristics of high- risk travel		Further informatio	
accinations requi	red for entry		1	
Yellow Fever	Countries that require a certificate of yellow fever vaccination among Africa and Central and South America Refer to the National Medical Center or quarantine stations no less than 10 days before arrival		1 dose, every 10 years	
Meningococcal	ningococcal No less than 10 days before arrival of a pilgrimage to Saudi Arabia			
/accinations recon	nmended when travelling to dev	reloping countries		
Hepatitis A	All developing countries	All travelers who are not immune to the virus (particularly those ≤ 30 years)	2 doses (at 0, 6~12 months)	
Typhoid Fever	Typhoid Fever India, Pakistan, Bangladeshi, Nepal, Indonesia, Philippine, Papua Negaunee Persons who travel more to 2 weeks or travel to rural and the second secon			
Meningococcal	Mid-Africa regions, Saudi Arabia	Persons on missionary work or humanitarian aid	1 dose; revaccination after 5 years	
Varicella	All developing countries	Some travelers aged less than 30 years who are not immune to the virus	Serology check neede 2 doses (at 0, 1~2 months)	
Measles/mumps/ rubella	All developing countries	Some travelers who are not immune to the virus	Serology check is no needed; 1 dose	
Rabies	South America, Mexico, Asia	Persons engaged in animal research, over the one-month period of humanitarian aid or travel to rural areas	3 doses	
Yellow Fever	Yellow fever risk areas of Africa and Central and South America	Jungle explorers	1 dose; refer to the National Institute of Health or quarantine stations	
Polio	India, Pakistan, Afghanistan, Uzbekistan, Tajikistan, Africa (including Nigeria)	Persons aged 40 years or less and who travel to rural areas	1 dose	
Influenza	Southern hemisphere	High-risk groups who travel during summer	1 dose	
Additional vaccina	tions when it is not general sigh	t-seeing travel		
Tick-borne Encephalitis Virus			Vaccines are not available in Korea	
Cholera		Persons engaged in humanitarian aid at refugee camps	Oral inactivated vacci (Dukoral) preferred	
/accinations or tes	ts necessary to check immunit	y upon international travel		
Refer to the Recom	mended Adult Immunization Sche	dule		

* Please refer to the website of the Korean Society for Infectious Disease (KSID) for this recommendation and any changes made.